Neuroinflammation and Alzheimer's disease: Lessons learned from 5-lipoxygenase

Translational Neuroscience

Volumn 5, Issue 3, 2014, Pages 197-202

  Joshi, Yash B ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 lipoxygenase; Alzheimer's disease; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; CYTOKINE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; ASTROCYTE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENCEPHALITIS; ENZYME INHIBITION; HUMAN; IMMUNE RESPONSE; MICROGLIA; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84906270444     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/s13380-014-0225-7     Document Type: Article

References (49)

1. Alzheimer's Association, Alzheimer's disease facts and figures, 2014, 10, 2, available at http://www.alz.org/downloads/Facts-Figures-2014.pdf
2. Holtzman D.M., Morris J.C., Goate A.M., Alzheimer's disease: the challenge of the second century, Sci. Transl. Med., 2011, 3, 77sr1
3. Ono K., Yamada M., Low-n oligomers as therapeutic targets of Alzheimer's disease, J. Neurochem., 2011, 117, 19-28
4. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I., Tau in Alzheimer disease and related tauopathies, Curr. Alzheimer Res., 2010, 7, 656-664
5. Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome, Neuron, 2004, 43, 321-332 (Pubitemid 39061125)
6. Oddo S., Caccamo A., Tran L., Lambert M.P., Glabe C.G., Klein W.L., et al., Temporal profile of amyloid-β (Aβ) oligomerization in an in vivo model of Alzheimer's disease. A link between Aβ and tau pathology, J. Biol. Chem., 2006, 281, 1599-1604
7. Rao K.S., Britton G.B., Fernandez P.L., Potential immunotargets for Alzheimer's disease treatment strategies, J. Alzheimers Dis., 2010, 33, 297-312
8. Sheng J.G., Mrak R.E., Grifin W.S., Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms, Acta Neuropathol., 1997, 94, 1-5 (Pubitemid 27289095)
9. Sheng J.G., Mrak R.E., Grifin W.S., Glial-neuronal interactions in Alzheimer's disease: progressive association of IL-1α+ microglia and S100β+ astrocytes with neurofibrillary tangle stages, J. Neuropathol. Exp. Neurol., 1997, 56, 285-290 (Pubitemid 27461169)
10. Hickman S.E., Allison E.K., El Khoury J., Microglial dysfunction and defective β-amyloid clearance pathways in aging Alzheimer's disease mice, J. Neurosci., 2008, 28, 8354-8360
11. Johnston H., Boutin H., Allan S.M., Assessing the contribution of inflammation in models of Alzheimer's disease, Biochem. Soc. Trans., 2011, 39, 886-890
12. D'Andrea M.R., Cole G.M., Ard M.D., The microglial phagocytic role with specific plaque types in the Alzheimer's disease brain, Neurobiol. Aging, 2004, 25, 675-683 (Pubitemid 38686491)
13. Permanne B., Adessi C., Saborio G.P., Fraga S., Frossard M.J., Van Dorpe J., et al., Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a β-sheet breaker peptide, FASEB J., 2002, 16, 860-862
14. Krabbe G., Halle A., Matyash V., Rinnenthal J.L., Eom G.D., Bernhardt U., et al., Functional impairment of microglia coincides with betaamyloid deposition in mice with Alzheimer-like pathology, PLoS One, 2013, 8, e60921
15. Morales I., Jimenez J.M., Mancilla M., Maccioni R.B., Tau oligomers and fibrils induce activation of microglial cells, J. Alzheimer Dis., 2013, 141, 495-505
16. Bhaskar K., Konerth M., Kokiko-Cochran O.N., Cardona A., Ransohof R.M., Lamb B.T., Regulation of tau pathology by the microglial fractalkine receptor. Neuron, 2010, 68, 19-31
17. Shefield L.G., Marquis J.G., Berman N.E., Regional distribution of cortical microglial parallels that of neurofibrillary tangles in Alzheimer's disease, Neurosci. Lett., 2000, 285, 165-168 (Pubitemid 30252054)
18. Wright A.L., Zinn R., Hohensinn B., Konen L.M., Beynon S.B., Tan R.P., et al., Neuroinflammation an neuronal loss precede Aβ plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease, PloS One, 2013, 8, e59586
19. Blasko I., Veerhuis R., Stampfer-Kountchev M., Saurwein-Teissl M., Eikelenboom P., Grubeck-Loebenstein B., Costimulatory efects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes, Neurobiol. Dis., 2000, 7, 682-689 (Pubitemid 32044292)
20. Wang Y., Li M., Tang J., Song M., Xu X., Xiong J., et al., Glucocorticoids facilitate astrocytic amyloid-β peptide deposition by increased expression of APP and BACE1 and decreasing the expression of amyloid-β-degrading proteases, Endocrinology, 2011, 152, 2704-2715
21. Jo W.K., Law A.C., Chung S.K., The neglected co-star in the dementia drama: the putative roles of astrocytes in the pathogenesis of major neurocognitive disorders, Mol. Psychiatry, 2014, 19, 159-167
22. Garwood C.J., Pooler A.M., Atherton J., Hanger D.P., Noble W., Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture, Cell Death Dis., 2011, 2, e167
23. Zilka N., Kazmerova Z., Jadhav S., Neradil P., Madari A., Obetkova D., et al., Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways, J. Neuroinflammation, 2012, 9, 47
24. Li Y, Liu L, Barger S.W., Grifin W.S., Interleukin-1 mediates pathological efects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway, J. Neurosci., 2003, 23, 1605-1611 (Pubitemid 36314715)
25. Radmark O., Samuelsson B., Regulation of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis, Biochem. Biophys. Res. Comm., 2010, 396, 105-110
26. Bishayee K., Khuda-Bukhsh A.R., 5-lipoxygenase antagonist therapy: a new approach towards targeted cancer chemotherapy, Acta Biochim. Sin. (Shanghai), 2013, 45, 709-719
27. Lammers C.H., Schweitzer P, Facchinetti P., Arrang J.M., Madamba S.G., Siggins G.R., et al., Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling, J. Neurochem., 1996, 66, 147-152 (Pubitemid 26010775)
28. Chinnici C.M., Yao Y., Praticò D., The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old, Neurobiol. Aging, 2007, 28, 1457-1462 (Pubitemid 47081230)
29. Ikonomovic M.D., Abrahamson E.E., Uz T., Manev H., Dekosky S.T., Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease, J. Histochem. Cytochem., 2008, 56, 1065-1073
30. Firuzi O., Zhuo J., Chinnici C.M., Wisniewski T., Praticò, D., 5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease, FASEB J., 2008, 22, 1169-1178 (Pubitemid 351519971)
31. Chu J., Praticò D., Pharmacological blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model involvement of γ-secretase, Am. J. Pathol., 2011, 178, 1762-1769
32. Chu J., Giannopoulos P.F., Ceballos-Diaz C., Golde T.E., Praticò D., Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice, Mol. Neurodegener., 2012, 7, 1
33. Chu J., Praticò D., 5-Lipoxygenase as an endogenous modulator of amyloid β formation in vivo, Ann. Neurol., 2011, 69, 34-46
34. Imbimbo B.P., Giardina G.A., Γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes, Curr. Top. Med. Chem., 2011, 11, 15550-15570
35. Chu J., Giannopoulos P.F., Ceballos-Diaz C., Golde T.E., Praticò D., 5-Lipoxygenase gene transfer worsens memory, amyloid and tau brain pathologies in a mouse model of Alzheimer's disease, Ann. Neurol., 2012, 72, 442-454
36. Giannopoulos P.F., Chu J., Joshi Y.B., Sperow M., Li J.G., Kirby L.G., et al., Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease, Mol. Psychiatry, 2014, 19, 511-518
37. Chu J., Praticò D., 5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5, Neurobiol. Aging, 2013, 34, 1549-1554
38. Chu J., Li J.G., Ceballos-Diaz C., Golde T., Praticò D., The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence, Biol. Psychiatry, 2013, 74, 321-328
39. Chu J., Praticò D., Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model, J. Neuroinflmmation, 2012, 9, 127
40. Joshi Y.B., Giannopoulos P.F., Chu J., Praticò D., Modulation of lipopolysaccharide-induced memory insult, γ-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase, Neurobiol. Aging, 2014, 35, 1024-1031
41. Parachikova A., Vasilevko V., Cribbs D.H., LaFerla F.M., Green K.N., Reductions in amyloid-β-derived neuroinflammation, with minocycline, restore cognition but do not significantly afect tau hyperphosphorylation, J. Alzheimers Dis., 2010, 21, 527-542
42. Ghosh S., Wu M.D., Shaftel S.S., Kyrkanides S., LaFerla F.M., Olschowka J.A., et al., Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model, J. Neurosci., 12, 5053-5064
43. Tsitsopoulos P.P., Marklund N., Amyloid-β peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies, Front. Neurol., 2013, 4, 79
44. Planel E., Richter K.E., Nolan C.E., Finley J.E., Liu L., Wen Y., et al., Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia, J. Neurosci, 2007, 27, 3090-3097 (Pubitemid 46474135)
45. Yanamandra K., Kfoury N., Jiang H., Mahan T.E., Ma S., Maloney S.E., et al., Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo, Neuron, 2013, 80, 402-414
46. McGeer P.L., Schulzer M., McGeer E.G., Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies, Neurology, 1996, 22, 1-4
47. Stewart W.F., Kawas C., Corrada M., Metter E.J., Risk of Alzheimer's disease and duration of NSAID use, Neurology, 1997, 48, 626-632 (Pubitemid 27120096)
48. Jaturapatporn D., Isaac M.G., McCleery J., Tablet N., Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease, Cochrane Database Syst. Rev., 2012, 2, CD006378
49. Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., et al., Variant of TREM2 associated with the risk of Alzheimer's disease, N. Engl. J. Med., 2013, 368, 107-116